Autumn leaves

PMDA Updates

October, 2018

News

1. The 18th ICDRA

Dr. Kondo giving a speech

The 18th International Conference of Drug Regulatory Authorities (ICDRA) was held in Dublin, Ireland from September 3 to 7. Dr. Tatsuya Kondo, Chief Executive; Dr. Nobumasa Nakashima, Senior Director for International Programs; and 2 staff members from PMDA as well as Mr. Naoyuki Yasuda, Office Director for International Regulatory Affairs, Ministry of Health, Labour and Welfare (MHLW) participated in the conference as speakers. ICDRA is the biennial meeting among pharmaceutical Regulatory Authorities organized by WHO, and the 18th ICDRA held under the theme of "Smart Safety Surveillance: A life-cycle approach to promoting safety of medical products" consisted of Pre-ICDRA Meeting (September 3-4) which was open to Industry, and ICDRA (September 5-7) which was for Regulators only.

Topics discussed during the conference included "Risk-based inspections: potential for work-sharing", "Enabling access to innovative medical products in resource-limited settings" and "Regulatory collaboration, convergence and harmonization" in the Pre-ICDRA Meeting, and "Regulator's role in containing antimicrobial resistance", "Regulation of clinical trials: focus on patient safety" and "Safety of medical products throughout the product life cycle" in the main ICDRA. Approximately 300 people across the world participated in the conference, including from Europe, Asia and Africa, and had an active exchange of views on each topic.

The draft recommendations by WHO based on the conference is available at the following link.
http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/18-ICDRA_DraftRecommendations.pdf?ua=1

2. ICMRA Summit Washington Meeting

Group photo of participants

The ICMRA (International Coalition of Medicines Regulatory Authorities) Summit meeting was held in Washington D.C., the United States of America, from September 10 to 12. About 90 members from approximately 22 nations and regions participated. From PMDA, Dr. Tatsuya Kondo, Dr. Nobumasa Nakashima and one staff member from the Office of International Programs, and from MHLW, Mr. Kazuhiko Mori, Councilor and two staff members participated in this meeting.

On the first day, there were discussions on clinical trials for pediatric populations based on experiences in each region. On the second day, heads of agency level discussions were held in panel discussion and free discussion format on ensuring the quality of biosimilars, patient involvement in drug development, the applications of real world data, and a comprehensive policy framework for regenerative medicine products. On the third day, the ICMRA Innovation Project, Pharmacovigilance, the future of ICMRA, and other topics were discussed. From PMDA, Dr. Kondo participated as a panelist for the session on a comprehensive policy framework for regenerative medicines.

In addition, Dr. Kondo and Dr. Nakashima presented interim results on regulator's horizon scanning methodology analysis as part of the Innovation project led by Japan. PMDA also reported on the ICMRA website which is maintained and hosted by PMDA.

The next ICMRA meeting will be held on the margins of the DIA Annual Meeting in San Diego, the United States of America from June 23 to 27.

3. The 14th IMDRF Management Committee Meeting

From September 18 to 20, the 14th International Medical Device Regulators Forum (IMDRF) Management Committee (MC) Meeting was held in Beijing, China, and three staff members from PMDA's Office of International Programs along with a staff from Ministry of Health, Labour and Welfare (MHLW) attended as the MC Members.

On the first day, an open IMDRF Stakeholder Forum was held with approximately 300 participants including members from MC and industry, and active discussions were held on issues of interest to industries such as development of robotic medical devices. The MC members from Japan provided an outline of recent Japanese regulatory efforts, and a progress report of the Medical Device Adverse Event Terminology Working Group (chaired by Japan). The second and the third day of the meeting were dedicated to the closed sessions for regulators and official invited observers only, where, in addition to the guidance documents developed by each working group, new work items were discussed. In this meeting, the MC approved the drafts on "Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices" proposed by the Good Regulatory Review Practice Working Group, "Definitions for Personalized Medical Devices" proposed by the Personalized Medical Devices Working Group, and "Optimizing Standards for Regulatory Use" proposed by the Standards Working Group as final documents.

On September 17, prior to the IMDRF meeting, a workshop sponsored by GMTA (The Global Medical Technology Alliance) was held. Medical Device Single Audit Program (MDSAP) Regulatory Authority Council (RAC) meeting was also held in the afternoon and Japanese delegates attended as a member country. The next IMDRF MC Meeting will be held in Moscow, Russia, in March 2019.

The details of the 14th IMDRF MC Meeting will be available at the following web site.
http://www.imdrf.org/meetings/meetings.asp

4. Call for application to PMDA-ATC Pharmacovigilance Seminar 2019 starts

PMDA Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) will hold a seminar entitled "PMDA-ATC Pharmacovigilance Seminar 2019" from February 4 to 7, 2019. This four-day seminar is designed for overseas regulatory authority officials who are engaged in pharmacovigilance activities. The Seminar includes lectures, group discussions with the training objective of acquainting the participants with knowledge that they could utilize in order to enhance the pharmacovigilance system in their countries/regions: The importance of harmonized regulatory strategy in ICH and Council for International Organizations of Medical Sciences (CIOMS) and regulatory updates to ensure compliance with new pharmacovigilance, risk management, and adverse event reporting, etc.; The risk management tools for pharmacovigilance and risk minimization action per safety specifications identified by signal detection and benefit-risk analysis; The importance of collection and accumulation of adverse drug reaction reports and methodology of signal detection using such accumulated data, from the point of view of pharmacoepidemiology; and The Benefit-Risk analysis through the life cycle of marketed medicinal products and the appropriate system for providing the updated information to stakeholders using labeling and periodic reports such as Periodic Benefit Risk Evaluation Report (PBRER).

The Seminar is held as a workshop of the Asia-Pacific Economic Cooperation, Life Sciences Innovation Forum, Regulatory Harmonization Steering Committee (APEC-LSIF-RHSC) Center of Excellence; however, the Seminar is open to non-APEC economies as well.

Please refer to the following web site for the details of PMDA-ATC Pharmacovigilance Seminar 2019.
http://www.pmda.go.jp/english/symposia/0137.html

English translations of review reports

The followings are current information about English version of review reports on PMDA web site.

Pharmaceuticals

http://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html

Brand Name	Non-proprietary Name	Posting date
Keytruda Injection	pembrolizumab (genetical recombination)	September 25

Ximency Combination Tablets	daclatasvir hydrochloride/asunaprevir/beclabuvir hydrochloride	October 12
Olumiant Tablets	baricitinib	October 17

Safety Information

Risk Information which some safety measures might be taken (September 28, 2018)

- Lamotrigine
- Secukinumab (genetical recombination)
- Lenvatinib mesilate

http://www.pmda.go.jp/english/safety/info-services/drugs/risk-communications/0001.html

Pharmaceuticals and Medical Devices Safety Information No. 357, October 16, 2018

1. Initiative of Revision of the Manuals for Management of Various Serious Adverse Drug Reactions (Part 2)
2. Summary of the Relief System for Adverse Drug Reactions and Request for Cooperation with the System
3. Revision of Precautions (No. 297)
Amantadine hydrochloride (and 13 others)
4. List of Products Subject to Early Post-marketing Phase Vigilance

http://www.pmda.go.jp/english/safety/info-services/drugs/medical-safety-information/0016.html

Pharmaceuticals Revisions of PRECAUTIONS, October 16, 2018

- Atorvastatin calcium hydrate
- Ezetimibe/atorvastatin calcium hydrate
- Pravastatin sodium
- Amlodipine basilate/atorvastatin calcium hydrate
- Clinofibrate
- Clofibrate
- Simvastatin
- Pitavastatin calcium hydrate
- Fenofibrate
- Bezafibrate
- Fluvastatin sodium
- Pemafibrate
- Rosuvastatin calcium

http://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0006.html

Pharmaceuticals Revisions of PRECAUTIONS, October 23, 2018

- Lamotrigine
- Secukinumab (genetical recombination)
- Lenvatinib mesilate

http://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0006.html

Events

Conferences/Meetings PMDA hosts or participates in:

Date	Title	Location
November 10-15	ICH week	Charlotte
November 12-16	PMDA-ATC Medical Devices Seminar 2018	Tokyo
November 26-30	PMDA-ATC GMP Inspection Seminar 2018	Tochigi

December 3	3rd Brazil-Japan Seminar on Regulations on Pharmaceuticals and Medical Devices	Tokyo

Reports from overseas

Our officers deliver lively reports of their activities at their stationed overseas authorities.

Introduction of Japanese regulatory measures related to paediatric medicines in Paediatric Committee (PDCO)

The European Regulation on paediatric medicines (Regulation (EC) No 1901/2006) has been implemented since 2007 in the EU, including, for example, the requirement for the development of paediatric medicines. A 10-year report on the EU paediatric regulation was issued in 2017 to summarize implementation status of these regulations and indicate potential further activities related to paediatric medicines.

In this context, the Paediatric Committee (PDCO), one of scientific committees managed by EMA, provided Japan with the opportunity to explain Japanese regulatory measures related to paediatric medicines in June 2018. It was explained in the PDCO that although there is no legal obligation to develop paediatric medicines in Japan, unlike in Europe, a variety of regulatory measures from the medicine development phase to data collection/safety measures in post-marketing phase are taken, in cooperation with stakeholders such as academic societies and patient groups, through the PMDA Paediatric Working Group and relevant departments in MHLW, in order to prepare an environment where more pediatric medicines can be used.

In the PDCO, we actively exchanged opinions on, for example, how to grasp the needs of pediatric medicines, how to prioritize them, and how to utilize post-marketing data in regulatory decision-making. This opportunity was so meaningful to expect further advances in international cooperation in the field of pediatric medicines.

Mr. Hideyuki Kondo
PMDA's International Liaison Officer stationed at EMA in the United Kingdom

---

Workshop regarding Analytical Quality by Design

The United States Pharmacopeial (USP) Convention held the workshop discussing on Analytical Quality by Design (AQbD) on Sep 24th and 25th[1].

The principle of "Quality by Design (QbD)", which is the concept of developing manufacturing process of pharmaceuticals by systematic approach, was introduced into Japan by International Council for Harmonisation (ICH)-Q8 guideline[2] in 2006. AQbD has the challenge to apply this principle of "QbD" to the development of analytical methods. USP has been discussing principles around AQbD since 2013[3-7]. The method developments based on AQbD are thought to be consisting of i) setting Analytical Target Profile (ATP), which is the performance criteria expected to the method, ii) identification of the factor to influence testing results, and iii) determination of parameters of analysis for normal operations. AQbD also includes continuous improvements of methods based on novel knowledge. As a result, analysts can establish robust and better analytical methods with AQbD. In this workshop, there are a lot of practical discussions regarding such as needs for establishing the unite terminology and how to describe ATPs.

1) http://www.usp.org/events-training/workshops/enhanced-approaches-for-analytical-procedure-lifecycle
2) http://www.pmda.go.jp/int-activities/int-harmony/ich/0048.html
3) Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification. USP Pharmacopeial Forum 39(5), 2013.
4) Fitness for Use: Decision Rules and Target Measurement Uncertainty. USP Pharmacopeial Forum 42(2), 2016.
5) Analytical target profile (ATP): Structure and application throughout the analytical lifecycle. USP Pharmacopeial Forum 42(5), 2016.
6) Analytical control strategy. USP Pharmacopeial Forum 42(5), 2016.
7) Proposed New USP General Chapter: The Analytical Procedure Lifecycle ⟨1220⟩. USP Pharmacopeial Forum 43(1), 2017

Dr. Hiroshi Takeda
PMDA's Liaison Officer stationed at USP in the U.S.A
